Christopher Ogden - Feb 14, 2022 Form 3 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Interim Principal Accounting Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Stock symbol
CTMX
Transactions as of
Feb 14, 2022
Transactions value $
$0
Form type
3
Date filed
3/9/2022, 05:06 PM
Next filing
Aug 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTMX Common Stock 7.29K Feb 14, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTMX Stock Option (Right to Buy) Feb 14, 2022 Common Stock 68K $4.97 Direct F3
holding CTMX Stock Option (Right to Buy) Feb 14, 2022 Common Stock 14.6K $4.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2 Includes 7,288 RSUs.
F3 25% of the shares subject to the option vest on the one-year anniversary measured from August 2, 2021 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F4 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Remarks:

Interim Principal Accounting Officer